Targeted cytotoxic delivery: payload and linker design, the antigens that make a tumour addressable, and how ADCs perform once the obvious targets are taken.
BL-B01D1-101 is an open-label, multicenter phase I study of izalontamab brengitecan (iza-bren; BL-B01D1), an EGFR-HER3 bispecific antibody-drug conjugate carrying a topoisomerase I inhibitor payload. The phase Ib extensive-stage small cell lung cancer (SCLC) cohort treated 52 patients who had progressed after platinum-based chemotherapy and a PD-(L)1 inhibitor.
The phase 3 TAISHAN-302 trial's interim analysis reports that the B7-H3-targeted antibody-drug conjugate tambotatug pelitecan (Tam-Peli) significantly extends overall and progression-free survival compared with topotecan in patients with small-cell lung cancer (SCLC) that relapsed after platinum-based chemotherapy.
A single-center, non-randomized phase 2 basket trial tested ado-trastuzumab emtansine (T-DM1) across five disease-specific cohorts of HER2-amplified solid tumors, asking whether a shared molecular driver predicts benefit from a HER2-targeted antibody-drug conjugate regardless of tumor origin.
A single-center, investigator-initiated Phase II trial using a Simon two-stage design tested sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate, in 50 evaluable patients with recurrent or persistent endometrial cancer who had progressed after platinum-based chemotherapy, enrolled between March 2020 and December 2024.
Phase 1, first-in-human dose-escalation trial of DYP688 — an antibody-drug conjugate that targets the melanocyte antigen PMEL and delivers a Gq/11 signaling inhibitor payload — in 66 patients with metastatic uveal melanoma and other GNAQ/GNA11-mutant melanomas, a population largely excluded from the only approved therapy for this disease.
The Phase III OptiTROP-Lung04 trial randomized 376 patients with EGFR-mutated advanced NSCLC that progressed after EGFR-TKI therapy to sacituzumab tirumotecan (sac-TMT) monotherapy or platinum-based chemotherapy